Technology
About NAD+
A vital molecule for healthy aging that decreases with age
Nicotinamide Adenine Dinucleotide (NAD+) plays a pivotal role in aging, longevity, immunity and DNA repair (Navas & Carnero 2021). This molecule has gained significant attention in recent years among scientists, longevity experts and in wider contexts for its likely role in extending healthspan.
The catch-22 is that at its core, biological aging is driven by depletion of NAD+, while NAD+ levels diminish as we age. As our indigenous NAD+ levels decrease, our cells become deprived of the energy they need to carry out their normal functions, leading to cellular exhaustion, dysfunction and onset of age-related diseases.
Unfortunately, today there is no scientifically reliable way to restore cellular availability of NAD+ in humans.
Our Technology
PNP inhibitor, MS 001
The first disease-targeting therapy that reliably restores cellular availability of NAD+.
Our lead compound, MS 001 , is a potent and selective inhibitor of purine nucleoside phosphorylase (PNP) proven to:
- Achieve >80% PNP inhibition at low doses in human studies;
- Restore NAD+ to its prime levels in the brain, muscle and blood circulation in mice;
- Significantly reduce LDL-cholesterol and blood glucose at low, oral doses.
By reliably restoring NAD+ levels in specific tissues like the brain, muscle and blood, where cellular exhaustion gives rise to serious, chronic diseases, our technology holds great promise for patients suffering from or at risk of cardiovascular, metabolic and neurodegenerative conditions.
MS 001 combines the safety of a drug established from Phase I and II studies with the ground-breaking potential of a new, patented chemical entity with a novel method of use.
How It Works
MS 001’s Mechanism of Action
PNP is an enzyme widely distributed in the body that limits the body’s ability to synthesize NAD+ and shortens the therapeutic window of NAD+ elevation. MS 001 binds to PNP and inactivates its catalytic activity, leading to sustained NAD+ elevation via the following mechanisms
- Inhibition of NR Breakdown: By inhibiting PNP, MS 001 limits the breakdown of the building blocks of NAD+, thereby increasing the body’s ability to synthesize it. PNP catalyzes the degradation of highly efficient NAD+ precursors, Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR). NR and NMN are both naturally produced by the body as part of the NAD+ biosynthesis pathway and can be supplemented (so far, to a limited extent) by dietary sources or supplements.
- Sparing Phosphoribosyl Pyrophosphate (PRPP): PRPP is an essential cofactor needed for NAD+ biosynthesis. MS 001 increases bioavailability of PRPP through inhibiting the biochemical pathways that consumes PRPP.
MS 001’s Mechanism of Action
PNP is an enzyme widely distributed in the body that limits the body’s ability to synthesize NAD+ and shortens the therapeutic window of NAD+ elevation. MS 001 binds to PNP and inactivates its catalytic activity, leading to sustained NAD+ elevation via the following mechanisms :
- Inhibition of NR Breakdown: By inhibiting PNP, MS 001 limits the breakdown of the building blocks of NAD+, thereby increasing the body’s ability to synthesize it. PNP catalyzes the degradation of highly efficient NAD+ precursors, Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR). NR and NMN are both naturally produced by the body as part of the NAD+ biosynthesis pathway and can be supplemented (so far, to a limited extent) by dietary sources or supplements.
- Sparing Phosphoribosyl Pyrophosphate (PRPP): PRPP is an essential cofactor needed for NAD+ biosynthesis. MS 001 increases bioavailability of PRPP through inhibiting the biochemical pathways that consumes PRPP.
